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Abstract
Background and Objective: The 2-Butoxyethanol (2BE) rat model of human hemolytic disorders has been used widely to evaluate
hemolysis and thromboembolic manifestations of different organs associated with sickle cell disease and $-thalassemia, however, studies
on nitric oxide metabolism are far more scarce. This study investigated the effects of Solenostemon  monostachyus  leaf extract
supplementation  on  2BE-induced  changes  of  inducible  nitric  oxide  synthase  (iNOS)  levels  and  mRNA  expression  in  female  rats.
Materials and Methods: Young female rats were divided into seven groups (Group A-G). All groups, except for group A, were exposed
to 2BE. The treatments assignments were as follows, group C: Caffeic acid, group D: Ciklavit (herbal formulation  of  Cajanus  cajan  (L.)
Mill sp.), group E-G: S. monostachyus  (150, 200 and 250 mg kgG1 b.wt.), respectively. Liver and plasma iNOS levels, as well as mRNA
expression of liver arginase-1 and iNOS, were assessed. Histopathological evaluation of the liver was also performed. The results were
statistically analyzed for significant effects at p<0.05 using one-way analysis of variance (ANOVA). Results: Liver and plasma iNOS were
significantly  reduced  (p<0.05)  in  group  G,  whereas  liver  iNOS  was  significantly  increased  (p<0.05)  in  group  D-F  compared  with
group B, iNOS mRNA expression was reduced, while arginase-1 mRNA expression was increased in group E-G compared with group B. 
Conclusion: Administration of S.  monostachyus  (250 mg kgG1 b.wt.) in the 2BE hemolytic rat model modulated plasma and liver iNOS
levels and iNOS mRNA expression.
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INTRODUCTION
Hemolytic anemia, a hemolytic disorder, is caused by
increased red blood cell destruction that exceeds the rate of
production by the bone marrow. Hemolytic disorders
represent approximately 5% of all anemia-related diseases and
hemolytic disorder complications, such as thalassemia and
sickle cell disease, can cause chronic hemolysis and
thromboembolic manifestations in different organs1-3.
Exposing Fischer F344 rats to 2-Butoxyethanol (2BE) has been
used as an experimental model to study hemolytic disorders,
such as sickle cell disease, B-thalassemia and associated
complications4-6.
Improper management of complications associated with
hemolytic disorders contributes to low survival rates. However,
recent medical advances in the management of sickle cell
disease, thalassemia and other hemolytic anemias, stemming
from a better understanding of the pathophysiology of these
diseases, have led to a significant increase in life expectancy.
Nonetheless, due to the high costs associated with clinical
management, there remains a need for alternatives in
resource-poor settings7. The-blood boosting potential of
several plant extracts with anti-sickling properties have been
previously reported8,9; however, there is paucity of data on the
molecular mechanism of action underlying the effects of these
plant extracts.
Solenostemon monostachyus (P. Beauv) Briq. (family
Lamiaceae) is an herb that grows in West and Central Africa. It
occurs as an annual weed in anthropogenic habitats and rocky
savannahs, is slightly succulent and aromatic and grows up to
100 cm tall10. The aerial parts of the plant are used in various
decoctions traditionally used to treat stomach ulcers, fever,
malaria, hemorrhoids and other inflammatory diseases11,12.
Decoctions of the plant are also used to treat hypertension13.
Phytochemical studies on Solenostemon monostachyus  (S. 
monostachyus)  have revealed the presence of water, proteins,
lipids, glucids, calcium, essential oils and phytoconstituents,
such as diterpenoids, flavonoids, coumarin and
polyphenol10,14-16. Biological studies of the plant indicate that
it has antioxidant, antihypertensive, antimicrobial and 
antiulcer  properties15-20.  In  addition,  Afolabi  et  al.8 reported
anti-sickling properties of the S. monostachyus methanolic
leaf extracts in vitro.
Studies of sickle cell disease and thalassemia-associated
complications have indicated that inflammation and oxidant
stress are important factors in disease progression21-23. These
findings have largely predicated the use of antioxidant
supplements      and      anti-inflammatory      agents      in      the
management of these hemolytic disorders. Nitric oxide (NO)
has emerged as a mediator of inflammation, with the enzyme
inducible nitric oxide synthase (iNOS) being primarily
responsible for the role of NO in inflammation24. NO
modulates vascular permeability, expression of adhesion
molecules, leucocyte recruitment and leucocyte and platelet
adhesion and aggregation25. These actions are important for
the management of SCD and $-thalassemia-associated
complications.
This study evaluated plasma and liver levels of iNOS and
iNOS mRNA expression in 2BE-exposed Fischer F344 female
rats as a model of human hemolytic disorders. This study also
investigated the effects of  S.  monostachyus  leaf extract
supplementation on 2BE-induced changes in plasma and liver
levels of iNOS and iNOS mRNA expression.
MATERIALS AND METHODS
Plant materials: Solenostemon  monostachyus  (P. Beauv)
Briq leaves (FH1108913) were sourced within the campus of
Covenant University, Ota, Ogun state in Nigeria. The plant was
identified internally by the Applied Biology Unit of the
Biological Science Department, Covenant University and
externally at the Herbarium of Forest research Institute Nigeria
(FRIN), Ibadan in Nigeria. The leaves were air dried at an
ambient temperature for 2 weeks and then blended into
coarse powder.
Extraction: Extraction was performed by a modification of the
rotary evaporation method as described by Mojisola et al.9
Coarse powder was soaked in absolute methanol for 72 h at
room temperature. Then, it was filtered and the filtrate was
evaporated in vacuo with a rotary evaporator (Stuart RE: 300)
at 20EC. Dried filtrate (5.0 g) was re-dissolved in 25 mL of
absolute methanol (Sigma, AR grade) and filtered to obtain
filtrate that was used as a working extract administered to the
treatment groups.
Animals: Forty-nine twelve-week old female albino rats were
randomly divided into 7 groups with 7 rats per group. The rats
were housed in cages and acclimatized for 3 weeks under the
same conditions prior to the experiment. This study was
approved by the Covenant University ethics committee
(reference number: CU/BIOSCRECU/BIO/2015/010).
Experiment and animal handling was performed according to
standard protocols approved by the animal ethics committee
of the Department of Biological Sciences, Covenant University,
Ota, Ogun state in Nigeria.
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Induction of hemolytic anemia in rats and treatment
administration: Hemolytic anemia with disseminated
thrombosis was induced in the experimental groups by oral
administration of 2-Butoxyethanol (250 mg kgG1 b.wt.)
dissolved in distilled water. Oral administration was performed
for 4 days as previously described6. A 0.015-0.025% portion of
working extract/body weight was administered to the
experimental rats, this concentration is sufficient to produce
an accurate model as well as to prevent harming the rats used
for this study.
Experimental groups included the following:
C Group   A   (control):   An   aliquot   of   5   mL   normal
saline kgG1 b.wt., was administered
C Group B (2BE): An aliquot of 250 mg 2-Butoxyethanol
(2BE) kgG1 b.wt., was administered for 4 days
C Group C (CF-A): An aliquot of 250 mg 2-Butoxyethanol
(2BE) kgG1 b.wt., was administered for 4 days followed  by 
1  mL  of  caffeic  acid kgG1  b.wt.,  for 5 days
C Group D (CKV): An aliquot of 250 mg 2-Butoxyethanol
(2BE) kgG1 b.wt., was administered for 4 days followed by
1 mL ciklavit kgG1 b.wt., for 5 days
C Group E (SM-150): An aliquot of 250 mg 2-Butoxyethanol
(2BE) kgG1 b.wt., was administered for 4 days followed by
150  mg   S.   monostachyus   leaf   extract   kgG1   b.wt.,  for
5 days
C Group F (SM-200): An aliquot of 250 mg 2-Butoxyethanol
(2BE) kgG1 b.wt., was administered for 4 days followed by
200  mg  S.  monostachyus   leaf  extract  kgG1  b.wt.,  for
5 days
C Group G (SM-250): An aliquot of 250 mg 2-Butoxyethanol
(2BE) kgG1 b.wt.,  was  administered  for  4  days  followed
by  250  mg  S.  monostachyus  leaf extract kgG1 b.wt., for
5 days
Sample collection: At the end of the experiments, blood was
drawn by cardiac puncture and livers were harvested from rats
under mild anesthesia using diethyl ether. Blood was
dispensed into EDTA tubes. Whole blood was used for total
and differential white blood cell (WBC) counts while plasma
was  obtained  after  blood  samples  were  centrifuged  at
4000 rpm for 10 min. Plasma was stored at -20EC until
analyzed. A 0.2 g sample of freshly harvested liver was
homogenized in phosphate buffered saline (PBS) while the
other samples were fixed in 10% neutral-buffered formalin for
histological analysis.
Determination of sICAM-1 levels: The concentration of
plasma sICAM was determined by enzyme-linked
immunosorbent assay  (ELISA)  using   a  rat  sICAM-1  ELISA  kit
(Hangzhou East Biopharm Co. Ltd, China). Plasma samples,
calibrators and quality controls were added to microtitre plate
wells and streptavidin-HRP conjugate was added to all wells
immediately following. The  plate  was  incubated  at  37EC  for
1 h and washed thereafter with wash buffer. Chromogen was
also added and the plate was incubated at 37EC for 10 min.
The reaction was stopped and optical density was measured
at 450 nm using an ELISA reader. sICAM concentration was
extrapolated from the calibration curve obtained.
Determination of iNOS levels: Concentrations of iNOS in
plasma and liver homogenates were measured using a rat
iNOS ELISA kit (Cloud-Clone Corp., USA). Plasma samples,
calibrators and quality controls were added to microtitre plate
wells and incubated at 37EC for 2 h. A secondary antibody was
added after decanting the plate content and incubated at
37EC for 1 h. Microtitre plate wells were washed, an enzyme
conjugate was added and it was incubated at 37EC for 30 min.
Microtitre plate wells were washed, chromogen was added
and it was incubated for 20 min at 37EC. The reaction was
stopped and optical density was measured at 450 nm using an
ELISA reader. iNOS concentration was extrapolated from the
calibration curve obtained.
RNA extraction: mRNA was extracted from liver samples using
an RNA isolation kit (Aid lab Biotechnologies Co. Ltd, China).
Fresh liver tissues were minced into small pieces and 350 µL
(<20 mg tissue) of Buffer RLT Plus (pH 7.0) was added, it was
then  homogenized  using  an  electronic  tissue  homogenizer
(JP Selecta  S. A.  Mechanical  vortex-VIB  machine  for  test
tube, Model number 7001725, Abrera, Barcelona). The
homogenized lysate was centrifuged at 13,000 rpm for 3 min
and the supernatant was carefully transferred into a DNA
elimination column, this was then centrifuged at 13,000 rpm
for 60 sec. An equal volume of 70% ethanol (Sigma; AR grade)
was added to the flow-through. About 700 µL of the mixture
was transferred into a RNA binding column and centrifuged at
13,000 rpm for 30 sec. About 700 µL of Buffer RW1 was then
added to the column. The mixture was incubated at room
temperature  for  1  min  and  centrifuged  at  12,000 rpm  for
30 sec. About 500 µL wash buffer RW was added and the
mixture centrifuged at 12,000 rpm for 30 sec. This step was
then  repeated.  The   column   was   placed   in   an   Rnase-free
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microcentrifuge tube and 30-50 µL of pre-warmed (90EC)
RNase free water was added to the center of the column
membrane,  this  was  then  incubated  at  room  temperature
for  1  min  and  centrifuged  at  12,000  rpm  for  1 min  to
elute  the  RNA.  Extracted  RNA  was  quantified
spectrophotometrically  with   a   NanoDrop   at   260  nm   and
the RNA purity was checked using 260-280 nm (A260/A280)
readings.  The  extracted  RNA  was  stored  at  -80EC  until
assayed.
cDNA synthesis and PCR amplification: Extracted RNA (1 µL)
was reverse transcribed to complementary DNA (cDNA) using
a TransScript II Two-step RT-PCR SuperMix (TransGen Biotech,
China) prior to PCR amplification. RT-PCR was carried out on
the cDNA synthesized from the liver samples using primer
pairs for iNOS and arginase-1. The sequences of the primers
used were as described previously by Li et al.26 rat $-actin, a
housekeeping gene, was used as an internal standard. All
primers were synthesized by SBS Genetech Co. Ltd, Beijing,
China.
C Rat iNOS: Sense primer: 5'-CTACCTACCTGGGGAACACCT
GGG-3'
C Anti-sense primer: 5'-GGAGGAGCTGATGGAGTAGTAG
CGG-3'
C Rat arginase-1: Sense primer: 5'- AAGAAAAGGCCGATTCA
CCT-3'
C Anti-sense primer: 5'- CACCTCCTCTGCTGTCTTCC-3'
The total reaction volume of 50 µL contained 2 µL of
cDNA, 1 µL of each primer, 25 µL of 2x TransTaq HiFi PCR
SuperMix II and 21 µL of RNAse-free water. RT-PCR was
performed in a programmable thermal cycler (BioRad C1000
Touch Thermal Cycler). Cycle conditions were as follow: 30 min
at 50EC and 5 sec at 85EC for RT-reaction, followed by 5 min at
94EC,  37  cycles  of  30  sec  at  94EC  (denaturation),  30 sec  at
50-60EC (annealing) and 2 kb minG1 at 72EC (extension) and a
cycle of 5 min at 72EC for final extension.
The solution containing PCR product (50 µL) was mixed
with 8 µL of loading dye and loaded onto 1% agarose gel
containing 4 µL ethidium bromide in 1x buffer. The samples
were run in 1x TBE buffer for 30 min at 100 V. The DNA markers
(TransGen Biotech, China) were run along with the samples as
a size marker. The specificity of the amplified bands was
validated by their predicted size. The resulting bands were
then visualized under UV-light and photographed using the
BioDoc-It® 220 imaging system Benchtop UV transilluminator.
Necropsy: Liver samples were processed, embedded in
paraffin, sectioned at 5-6 mm and stained with hematoxylin
and eosin (H and E) for microscopic examination to determine
definitive evidence of thrombosis and phagocyte infiltration
(macrophages and neutrophils).
Statistical analysis: A one-factor randomized complete block
design was used for this study. Data were analyzed using
MegaStat statistical software package for Windows (version
1.0.0.0) from Informer Technologies, Inc (Villaverde, Madrid,
Spain). Results were expressed as mean±standard deviation.
Mean differences were tested using one-way analysis of
variance (ANOVA) and pairwise comparisons were tested with
post-hoc tests. Values were considered statistically significant
at p<0.05.
RESULTS
Liver iNOS levels were significantly decreased (p<0.05) in
most of the treated group B, C, D, F and G compared with
control (group A), while plasma iNOS significantly were
reduced (p<0.05) in  group  G  that  was  administered  250 mg
S. monostachyus leaf extract kgG1 b.wt., compared with
control (group A). Liver and plasma iNOS levels were also
significantly reduced (p<0.05) in group G that was
administered 250 mg S. monostachyus leaf extract kgG1 b.wt.,
compared with the untreated hemolytic induced group
(group B), whereas liver iNOS levels were significantly
increased (p<0.05) in group D, E and F administered with
ciklavit,   150   mg   and   200   mg   S.   monostachyus   leaf
extracts  kgG1 b.wt., respectively compared with the untreated
hemolytic induced group (group B). There were significant
decreases   (p<0.05)   in   neutrophil   counts  in   group   C,   F
and  G  administered  with  cafeic  acid,  200 mg  and 250  mg
S. monostachyus  leaf  extracts  kgG1  b.wt.,  respectively
compared with group B, which is the untreated hemolytic
induced group (Table 1). In addition, there was reduced iNOS
mRNA expression in group B compared with control (group A),
iNOS  mRNA  expression  in  groups  administered  with 150,
200 and 250 mg  S.  monostachyus  leaf extracts kgG1 b.wt.,
(group E, F and G) were reduced compared with the control
and   the   untreated   hemolytic   induced   group   (group  A
and B).
Arginase-1 mRNA expression was higher in untreated
hemolytic induced group (group B) compared to the control
(group A), arginase-1 mRNA expression was also higher in
groups  administered   with  150, 200 and  250  mg  kgG1  b.wt., 
356
J. Biol. Sci., 17 (8): 353-361, 2017
Fig. 1: RT-PCR of liver arginase-1 and iNOS mRNA expression with $-actin as the internal standard
2BE: Group administered 2-butoxyethanol, C: Control group administered saline, CF-A: Group administered  caffeic  acid,  CKV:  Group  administered ciklavit,
iNOS: Inducible  nitric  oxide  synthase,  SM-150: Group administered 150 mg  S.  monostachyus  leaf extract kgG1 b.wt., SM-200:  Group  administered 200 mg
S. monostachyus  leaf extract kgG1 b.wt., SM-250: Group administered 250 mg S. monostachyus leaf extract kgG1 b.wt.
Table 1: Effect of oral administration of Solenostemon monostachyus on red cell indices
Variables Group A (Control) Group B (2BE) Group C (CF-A) Group D (CKV) Group E (SM 150) Group F (SM 200) Group G (SM 250)
WBC (x103) 7.0±1.7 6.1±2.2 6.6±1.0 6.9±0.8 6.5±1.7 6.6±0.1 6.5±1.8
Lymphocytes 76.3±5.5 73.6±4.7 81.0±4.0 75.7±5.0 77.9±7.2 81.8±8.0 79.7±5.6
Monocytes 1.3±1.9 0.0±0.0 1.9±2.3 1.3±1.5 1.4±2.2 0.0±0.0 0.3±0.8
Neutrophils 21.0±5.6 26.4±4.7 16.3±4.0# 24.0±4.9 20.4±7.4 17.8±8.5# 19.3±5.5#
Plasma sICAM 2.9±0.3 3.0±0.1 3.1±0.4 3.0±0.4 3.1±0.2 3.1±0.4 3.0±0.4
Plasma iNOS 3.3±0.5 3.0±0.3 2.4±1.3 3.9±1.6 3.9±0.9 2.8±0.8 1.1±0.3*#
Liver iNOS 41.7±4.3 28.4±2.5* 28.9±4.3* 33.8±0.7*# 37.8±5.0# 34.0±4.6*# 25.6±1.3*#
2BE: 2-Butoxyethanol, CF-A: Group administered caffeic acid, CKV: Group administered ciklavit, SM-150: Group administered 150 mg kgG1 b.wt., S. monostachyus leaf
extract, SM-200: Group administered 200 mg kgG1 b.wt., S. monostachyus leaf extract, SM-250: Group administered 250 mg kgG1 b.wt., S. monostachyus leaf extract,
values are expressed in Mean±SD (n = 7), *Significantly different from group A (control) at p<0.05, #Significantly different from group B (2BE) at p<0.05
S.    monostachyus      leaf      extracts      (group      E,      F      and
G)  compared  with  group  A  and  B,  serving  as  the control
and  the  untreated  hemolytic  induced  group,  respectively
(Fig. 1).
DISCUSSION
Hemolysis  and  thromboembolic  manifestations  in
organs associated with SCD and $-thalassemia have been
studied extensively using the 2BE F344 rat model; however,
studies on NO metabolism using this model are far scarcer.
Intravascular hemolysis contributes to endothelial dysfunction
in SCD and in other hemolytic conditions and is characterized
by a reduction in NO bioavailability and resistance27. The
present study found no differences in plasma iNOS levels
using  the  2BE  rat  model   of   hemolysis,   suggesting   that
2BE administration at the dose and duration applied in this
study,  as  in  previous  studies,  does  not  alter  plasma  iNOS
levels.
Erythrocyte  lysis  has  been  reported  to  lead  to  the
release of cell-free hemoglobin and enzyme arginase into
plasma, which independently results in reduced NO
bioavailability.  Free  heme  is  rapidly  reacts  with  and
destroys,  NO,  while  reactive  oxygen  species  produced  by
the  action  of  free  iron  acting  as  a  pro-oxidant  increases
the rate of NO consumption during  hemolysis.  The  released
enzyme,   arginase,   degrades  L-arginine,  the  obligate
substrate  for NO synthase, further reducing NO bioavailability,
which  is  supported  by  reports  of  low  plasma L-arginine
levels in SCD patients28. Under these conditions, eNOS is
uncoupled, producing superoxide forms rather than NO29,30.
Based on the results of this study, uncoupling, as observed
with eNOS, may not be applicable to iNOS in hemolytic
disorders; therefore, iNOS may be explored as a potential
therapeutic target for reversing the reduction of NO
bioavailability.
Liver resident macrophages, referred to as kupffer cells,
are  usually  involved  in  the  uptake  of   damaged   RBCs   and
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hepatic involvement in hemolytic disorders has been reported
in the 2BE F344 hemolytic rat model6. The present study found
reduced iNOS levels in liver tissue homogenates in the 2BE
F344 hemolytic rat model compared with controls. In
hemolytic disorders, increased phagocytosis of RBCs by
kupffer  cells  leads  to  increased  deposition  of  hemosiderin
and iron, thereby mediating hepatic oxidative stress. Oxidative
stress induction and subsequent activation of the signaling
pathways  for  transcription  factors  NF-kB,  AP-1  and  SP-1
have been reported to induce iNOS expression, thereby
increasing  NO  production31.  However,  increasing  iNOS
levels may not be possible in a state of reduced NO
bioavailability  and  NO  resistance,  as  supported  by  a  study
that showed increased arginase-1 mRNA expression and
decreased iNOS mRNA expression in the liver of the 2BE F344
hemolytic rat model32. Hepatic oxidative stress with the
production of superoxide radicals (@O2G) converts NO to
peroxynitrite, while arginase degrades L-arginine, making it
unavailable for NO production. These actions result in a state
of reduced NO bioavailability and NO resistance in the liver.
The reduction in iNOS levels found in this study may be due to
a loss of function of hepatocytes as supported by liver
histology.
Although treatment with caffeic acid did not change liver
iNOS levels, liver arginase-1 or iNOS mRNA expression,
treatment with ciklavit caused an increase in liver iNOS levels
without affecting liver arginase-1 or iNOS mRNA expression.
This finding demonstrates that caffeic acid may not ameliorate
changes in iNOS, while also suggesting a possible iNOS
sparring-ability for ciklavit. S. monostachyus treatment
increased  liver  iNOS  levels  without  increasing  liver  iNOS
mRNA    expression.    At    a    200    mg  kgG1   b.wt.,   dose   of
S.  monostachyus,  there was an increase in liver iNOS levels
and a decrease in liver iNOS mRNA expression, supporting the
iNOS-sparring ability of SM at 150 and 200 mg kgG1 b.wt.,
doses, which may not require corresponding alterations in
iNOS mRNA expression.  This  finding  may  have  been  caused
by S. monostachyus  at the level of post-transcriptional
modifications  of  iNOS  mRNA  or  by  miRNA, both of which
are not presently understood completely. In addition, this
finding may also have been the result of an increase in time
prior to degradation or half-life of iNOS through potent
scavenging  ROS  by S.  monostachyus,  thereby  reversing
hemolysis-induced oxidative stress.
The SM has been previously reported to have anti-
oxidative potential15-17. At a 250 mg kgG1 b.wt., dose, plasma
and liver iNOS levels were reduced, in addition to reductions
in liver arginase-1 and iNOS mRNA expression. This finding
could indicate a reversal of reduced NO bioavailability and NO
resistance. iNOS is tightly regulated by feedback mechanisms
that fine-tune its expression and NO is either produced
exogenously by NO donors or synthesized endogenously  as 
part  of  a  negative  feedback  loop  to down-regulate
expression33-35. iNOS-derived NO can inhibit iNOS  enzymatic 
function  through  transcriptional  and post-translational
modification36-38. This present study has demonstrated  for  the 
first  time  the  iNOS  modulatory effect of S. monostachyus;
however there is need for additional studies  to   understand 
 the   specific   mechanism   by   which S. monostachyus 
modulates iNOS to ascertain its utility in managing diseases,
such as asthma, arthritis, multiple sclerosis, colitis, psoriasis
and septic shock, in which aberrant iNOS induction has been
implicated.
Histopathological analysis of the liver revealed random
multifocal hepatocellular necrosis with intravascular thrombi
(congested blood vessels) in the 2BE group, which is
consistent with a previous report (Fig. 2)6. The 2BE F344
hemolytic rat model showed cirrhotic liver disease resulting
from inflamed hepatic parenchyma cells. The CF-A group
revealed microvascular thrombosis with moderate triaditis and
the CKV group revealed presence of microvascular thrombosis
with mild triaditis indicative of increased inflammation in the
bile ductule, hepatic venule and portal vein branch. Though
the potency of ciklavit to ameliorate the adverse effect of
sickle cell anemia on the liver has previously been reported39,
this study suggests that ciklavit may not be as highly effective
for individuals recovering from regenerative hemolytic
anemia.
It is also found that severe infiltration of
polymorphonuclear immune cells with hyperchromatic nuclei
in the 2BE F344 hemolytic rats treated with 150 mg kgG1 b.wt.,
S.  monostachyus,  indicating  cell  nuclei  degeneration  and
a  mild  loss  of  normal  architectural  structure  of  the  liver
due to cirrhosis. This group also had white patches and
discoloration, as well as gradually degenerated hepatic
parenchyma cells. Areas of mild necrosis were also observed
with  whitish  discoloration  and  there  was  an  absence  of
blood   vessels,   indicating   the   thrombolytic   potential   of
the S.  monostachyus  extract  at  250  mg  kgG1  b.wt.,
phagocytes were able to completely clear the damaged cells
at those sites. These findings also support a reversal of
reduced NO bioavailability and NO resistance, as NO has been
associated with increased wound healing and repair in tissue
injury40.
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Fig. 2(a-g): Hepatic sections of all groups (H and E stain x200), (a) Staining revealed normal features of the liver with evident
hepatic portal veins (thin arrow), triad (thick arrow) and parenchymal cells (head arrow), (b) Staining revealed
moderate necrosis (thin arrows) with gradual loss of architectural structure (head arrow) and congested vessels (thick
arrow), (c) Staining revealed congested vessels (thin arrows) with moderate triaditis (thick arrow), (d) Staining showed
the presence of mild triaditis (thin arrows) with congested vessels (thick arrow), (e) Staining showed the presence of
severe infiltration of polymorphs with hyper-chromatic nuclei (thin arrows) and a loss of normal architectural structure
(thick arrows), (f) Staining revealed heavy infiltration of polymorphs (thick arrow) with white patches, discoloration
(head arrow) and necrosis (thin arrows) and (g) Staining revealed areas of mild necrosis (thin arrows) with whitish
discoloration
CONCLUSION
Administration    of    a    250   mg   kgG1    b.wt.,    dose    of
S. monostachyus in the 2BE F344 hemolytic rat model
modulated plasma and liver iNOS levels and liver iNOS mRNA
expression. Therefore, S.  monostachyus  has potential for use
in the management of conditions associated with aberrant
iNOS induction.
SIGNIFICANCE STATEMENTS
This study identified part of the molecular mechanisms
supporting the use of Solenostemon  monostachyus (P.Beauv.)
Briq. leaf extract in the management of hemolysis and
thromboembolic manifestations associated with sickle cell and
other endemic diseases. The leaf extracts of Solenostemon
monostachyus  possess   anti-anemic,   anti-inflammatory   and
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thrombolytic effects when administered at a 250 mg kgG1
dose. The therapeutic activity of the extract works by
simultaneously lowering expression of aberrant iNOS, as well
as by increasing the expression of arginase. These findings
may help researchers develop a more enduring drug to
manage hemolytic disorders like sickle cell disease.
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